Titration

Paragon Genomics Launches ParagonDesigner™ Online Tool That Makes It Easy To Design Custom CleanPlex® NGS Assays

Retrieved on: 
Thursday, September 20, 2018
Genomics, Assay, Biochemistry, Titration, Omics, Nature

HAYWARD, Calif., Sept. 20, 2018 /PRNewswire/ -- Paragon Genomics, Inc. today announced the launch of ParagonDesigner , its web-based tool that enables rapid design of CleanPlex Custom NGS Panels.

Key Points: 
  • HAYWARD, Calif., Sept. 20, 2018 /PRNewswire/ -- Paragon Genomics, Inc. today announced the launch of ParagonDesigner , its web-based tool that enables rapid design of CleanPlex Custom NGS Panels.
  • "ParagonDesigner allows our customers to build CleanPlex Custom NGS assays with just a few clicks of the mouse," said Tao Chen, founder and CEO of Paragon Genomics.
  • Paragon Genomics design experts are available to provide hands-on personalized support to all ParagonDesigner customers, even for small orders.
  • With ParagonDesigner, users define the content of their custom NGS assays by submitting their targets online.

Paragon Genomics Launches ParagonDesigner™ Online Tool that MAKES IT Easy TO Design Custom CleanPlex® NGS Assays

Retrieved on: 
Thursday, September 20, 2018
Genomics, Assay, Biochemistry, Titration, Omics, Nature

HAYWARD, Calif., Sept. 20, 2018 /PRNewswire/ -- Paragon Genomics, Inc. today announced the launch of ParagonDesigner , its web-based tool that enables rapid design of CleanPlex Custom NGS Panels.

Key Points: 
  • HAYWARD, Calif., Sept. 20, 2018 /PRNewswire/ -- Paragon Genomics, Inc. today announced the launch of ParagonDesigner , its web-based tool that enables rapid design of CleanPlex Custom NGS Panels.
  • "ParagonDesigner allows our customers to build CleanPlex Custom NGS assays with just a few clicks of the mouse," said Tao Chen, founder and CEO of Paragon Genomics.
  • Paragon Genomics design experts are available to provide hands-on personalized support to all ParagonDesigner customers, even for small orders.
  • With ParagonDesigner, users define the content of their custom NGS assays by submitting their targets online.

Cell-Based Assays World Industry and Market 2018-2028 - Visiongain Report

Retrieved on: 
Wednesday, September 19, 2018
Assay, Biochemistry, Titration, Compound annual growth rate

The revenue of the cell-based assays market in 2017 is estimated at $13bn and is expected to grow at a CAGR of 9.2% in the first half of the forecast period.

Key Points: 
  • The revenue of the cell-based assays market in 2017 is estimated at $13bn and is expected to grow at a CAGR of 9.2% in the first half of the forecast period.
  • Visiongain estimated that the consumables and services segments accounted for 74.26% of the market.
  • In this brand new 241-page report you will receive 85 tables and 103 figures- all unavailable elsewhere.
  • The 241-page report provides clear detailed insight into the cell-based assays market.

The global cell viability assays market is projected to grow at a CAGR of 8.4%

Retrieved on: 
Wednesday, September 12, 2018
Biology, Cell biology, Nature, Laboratory techniques, Assay, Biochemistry, Titration, Viability assay, Stem cell

On the basis of cell type, the cell viability assays market is segmented into human cells, animal cells, and microbial cells.The human cells segment is expected to register the highest CAGR during the forecast period.

Key Points: 
  • On the basis of cell type, the cell viability assays market is segmented into human cells, animal cells, and microbial cells.The human cells segment is expected to register the highest CAGR during the forecast period.
  • On the basis of application, the cell viability assays market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications.
  • North America is expected to account for the largest share of the global cell viability assays market in 2018.
  • The report analyzes the various cell viability products and their adoption pattern.It aims at estimating the market size and future growth potential of the global cell viability assays market for different segments such as products, cell types, applications, end users, and regions.

Cell Viability Assays Market Worth $4.16 Billion by 2023

Retrieved on: 
Wednesday, September 5, 2018
Biology, Nature, Cell biology, Assay, Biochemistry, Titration, Viability assay, Stem cell, Plate reader

On the basis of product, the consumables segment is expected to account for the largest share of the Cell Viability Assays Market in 2018.

Key Points: 
  • On the basis of product, the consumables segment is expected to account for the largest share of the Cell Viability Assays Market in 2018.
  • Based on application, the Cell Viability Assays Market is segmented into drug discovery & development, basic research, stem cell research, clinical & diagnostic applications, and other applications.
  • In 2018, the drug discovery & development application segment is expected to account for the largest share of the global Cell Viability Assays Market.
  • North America is expected to account for the largest share of the Cell Viability Assays Market in 2018, followed by Europe and Asia Pacific.

The global protein binding assay market is projected to grow at a CAGR of 10.7%

Retrieved on: 
Monday, August 20, 2018
Chemistry, Laboratory techniques, Biochemistry, Assay, Titration, Nature, Dialysis

The protein binding assay market is projected to reach USD 425.7 million in 2023 from USD 256.1 million in 2018, at CAGR of 10.7% during the forecast period.

Key Points: 
  • The protein binding assay market is projected to reach USD 425.7 million in 2023 from USD 256.1 million in 2018, at CAGR of 10.7% during the forecast period.
  • Pharmaceutical and biotechnology companies are expected to account for the largest share of the protein binding assay market in 2018.
  • By end user, the protein binding assay market is divided into pharmaceutical & biotechnology companies, CROs, and other end users.In 2018, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the protein binding assay market.
  • On the basis of technology, the protein binding assay market is segmented into equilibrium dialysis, ultrafiltration, ultracentrifugation, and other technologies.The equilibrium dialysis segment is expected to account for the largest share of the protein binding assay market.

Procleix® Zika Virus Assay Approved by the FDA for Blood Screening on the Procleix® Panther® System

Retrieved on: 
Tuesday, August 14, 2018
Medicine, Chemistry, Laboratory techniques, Medical tests, Clinical medicine, Assay, Biochemistry, Titration, HIV, Zika virus, Zika fever, Viral load monitoring for HIV

The Procleix Zika Virus assay has been in use since June 2016 under an Investigational New Drug protocol to screen donated blood collected in the U.S.

Key Points: 
  • The Procleix Zika Virus assay has been in use since June 2016 under an Investigational New Drug protocol to screen donated blood collected in the U.S.
  • The assay is performed on the Procleix Panther system automated platform using nucleic acid technology (NAT), and enables blood banks and donor centers to enhance the safety of their blood supplies.
  • Grifols recently received FDA approval for two other assays on the Procleix Panther System - the Procleix Ultrio Elite (to screen for HIV-1, HCV, and HBV and detect HIV-2), and West Nile Virus assays.
  • The Procleix Panther system automates all aspects of NAT-based blood screening on a single, integrated platform.

Protein Binding Assays Market Worth $425.7 Million in 2023

Retrieved on: 
Friday, August 10, 2018
Chemistry, Membrane technology, Biochemistry methods, Assay, Biochemistry, Titration, Dialysis, Compound annual growth rate, Binding

On the basis of technology, the global Protein Binding Assays Market is divided into equilibrium dialysis, ultrafiltration, ultracentrifugation, and other technologies.

Key Points: 
  • On the basis of technology, the global Protein Binding Assays Market is divided into equilibrium dialysis, ultrafiltration, ultracentrifugation, and other technologies.
  • In 2018, the equilibrium dialysis segment is expected to grow at the highest CAGR in the Protein Binding Assays Market.
  • On the basis of end user, the global Protein Binding Assays Market is divided into pharmaceutical and biotechnology companies, CROs, and other end users.
  • In 2018, the CROs segment is expected to grow at the highest CAGR in the global Protein Binding Assays Market.

Microbiologics Expands Its Molecular Diagnostics QC Offering

Retrieved on: 
Tuesday, July 24, 2018
Assay, Biochemistry, Titration

SAINT CLOUD, Minn., July 24, 2018 /PRNewswire/ --Microbiologics, Inc. has launched a series of new panels for verification and routine quality control of common molecular assays.

Key Points: 
  • SAINT CLOUD, Minn., July 24, 2018 /PRNewswire/ --Microbiologics, Inc. has launched a series of new panels for verification and routine quality control of common molecular assays.
  • The eight new panels, designed to mimic patient sample processing, include convenient features such as pellets and swabs pre-pooled with multiple strains and room temperature storage.
  • "Molecular testing has become an essential tool in clinical laboratories experiencing large workloads, limited resources, and pressure to deliver accurate results quickly," said Brian Beck, Ph.D., Vice President of Research and Development.
  • "User experience and the specific testing processes for verification and routine quality control were top of mind when we designed our new panels.

Alveo Announces Appointments of CTO and Director of Assay Development

Retrieved on: 
Thursday, July 12, 2018
Assay, Biochemistry, Titration

Johnson Chiang, Ph.D., has been named Chief Technology Officer and Rixun Fang, Ph.D., has been appointed Director of Assay Development.

Key Points: 
  • Johnson Chiang, Ph.D., has been named Chief Technology Officer and Rixun Fang, Ph.D., has been appointed Director of Assay Development.
  • "Not only are they brilliant leaders in their fields, but they share the Alveo passion for creating better, more accessible ways to protect the health of humankind."
  • In his role as Chief Technology Officer, Dr. Chiang has a clear mission to ensure the success of Alveo's high-performance product development and commercialization.
  • As Director of Assay Development, Dr. Fang brings over 20 years of experience in molecular biology research and IVD product development to Alveo.